With the ‘fourth wave’ of COVID-19 in the US, Regeneron and GSK report high demand for their monoclonal antibody treatments
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.